Concepedia

Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia

Shin Yeu Ong, Colin Phipps, Chandramouli Nagarajan, Tiffany Tang, Soon Thye Lim, Yeow Tee Goh, Yuh Shan Lee

Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 11 citations · 13 references

DOI

Concepts

Abstract

Central nervous system (CNS) relapse occurs in 2–6% of patients with diffuse large B-cell lymphoma (DLBCL) and is a dismal diagnosis with poor outcomes. The National Cancer Comprehensive Cancer Net...

References

13

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Norbert Schmitz, Samira Zeynalova, Maike Nickelsen et al. · Journal of Clinical Oncology · 2016 · 445 citations

, , +13

A uniform activated B-cell–like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases

Sophie Camilleri‐Broët, Emmanuelle Crinière, Philippe Broët et al. · Blood · 2005 · 373 citations · Full text

, , +11

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma

Jeremy S. Abramson, Matthew D. Hellmann, Jeffrey A. Barnes et al. · Cancer · 2010 · 236 citations · Full text

, , +16

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

Kerry J. Savage, Graham W. Slack, Anja Mottok et al. · Blood · 2016 · 185 citations · Full text

, , +8

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

Chan Y. Cheah, Kirsten Herbert, Kacey O’Rourke et al. · British Journal of Cancer · 2014 · 132 citations · Full text

, , +16